vs
Side-by-side financial comparison of Insulet Corporation (PODD) and WATSCO INC (WSO). Click either name above to swap in a different company.
WATSCO INC is the larger business by last-quarter revenue ($1.5B vs $783.7M, roughly 2.0× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 6.1%, a 6.9% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 0.1%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -15.3%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Watsco, Inc. is a distributor of air conditioning, heating and refrigeration equipment, and related parts and supplies (HVAC/R) in the United States. Watsco was founded more than 60 years ago as a manufacturer of parts, components, and tools used in the HVAC/R industry. In 1989, the company shifted from manufacturing to distribution, by acquiring Gemaire Distributors Inc., a South Florida-based Rheem distributor.
PODD vs WSO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $1.5B |
| Net Profit | $101.6M | $92.9M |
| Gross Margin | 72.6% | 27.9% |
| Operating Margin | 18.7% | 7.2% |
| Net Margin | 13.0% | 6.1% |
| Revenue YoY | 31.2% | 0.1% |
| Net Profit YoY | 0.9% | -1.7% |
| EPS (diluted) | $1.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $783.7M | $1.6B | ||
| Q3 25 | $706.3M | $2.1B | ||
| Q2 25 | $649.1M | $2.1B | ||
| Q1 25 | $569.0M | $1.5B | ||
| Q4 24 | $597.5M | $1.8B | ||
| Q3 24 | $543.9M | $2.2B | ||
| Q2 24 | $488.5M | $2.1B |
| Q1 26 | — | $92.9M | ||
| Q4 25 | $101.6M | $71.7M | ||
| Q3 25 | $87.6M | $161.6M | ||
| Q2 25 | $22.5M | $183.6M | ||
| Q1 25 | $35.4M | $80.1M | ||
| Q4 24 | $100.7M | $96.8M | ||
| Q3 24 | $77.5M | $171.0M | ||
| Q2 24 | $188.6M | $181.4M |
| Q1 26 | — | 27.9% | ||
| Q4 25 | 72.6% | 27.1% | ||
| Q3 25 | 72.2% | 27.5% | ||
| Q2 25 | 69.7% | 29.3% | ||
| Q1 25 | 71.9% | 28.1% | ||
| Q4 24 | 72.1% | 26.7% | ||
| Q3 24 | 69.3% | 26.2% | ||
| Q2 24 | 67.7% | 27.1% |
| Q1 26 | — | 7.2% | ||
| Q4 25 | 18.7% | 6.4% | ||
| Q3 25 | 16.7% | 11.4% | ||
| Q2 25 | 18.7% | 13.2% | ||
| Q1 25 | 15.6% | 7.3% | ||
| Q4 24 | 18.3% | 7.8% | ||
| Q3 24 | 16.2% | 11.6% | ||
| Q2 24 | 11.2% | 12.6% |
| Q1 26 | — | 6.1% | ||
| Q4 25 | 13.0% | 4.5% | ||
| Q3 25 | 12.4% | 7.8% | ||
| Q2 25 | 3.5% | 8.9% | ||
| Q1 25 | 6.2% | 5.2% | ||
| Q4 24 | 16.9% | 5.5% | ||
| Q3 24 | 14.2% | 7.9% | ||
| Q2 24 | 38.6% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | $1.42 | $1.82 | ||
| Q3 25 | $1.24 | $3.98 | ||
| Q2 25 | $0.32 | $4.52 | ||
| Q1 25 | $0.50 | $1.93 | ||
| Q4 24 | $1.38 | $2.42 | ||
| Q3 24 | $1.08 | $4.22 | ||
| Q2 24 | $2.59 | $4.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $392.7M |
| Total DebtLower is stronger | $930.8M | — |
| Stockholders' EquityBook value | $1.5B | $3.2B |
| Total Assets | $3.2B | $4.6B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $392.7M | ||
| Q4 25 | — | $733.3M | ||
| Q3 25 | — | $524.3M | ||
| Q2 25 | — | $293.0M | ||
| Q1 25 | — | $431.8M | ||
| Q4 24 | — | $781.9M | ||
| Q3 24 | — | $550.0M | ||
| Q2 24 | — | $424.9M |
| Q1 26 | — | — | ||
| Q4 25 | $930.8M | $361.6M | ||
| Q3 25 | $934.9M | $340.8M | ||
| Q2 25 | $939.0M | $338.7M | ||
| Q1 25 | $1.6B | $346.4M | ||
| Q4 24 | $1.3B | $337.2M | ||
| Q3 24 | $1.4B | $321.0M | ||
| Q2 24 | $1.4B | $307.1M |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.5B | $2.8B | ||
| Q3 25 | $1.4B | $2.8B | ||
| Q2 25 | $1.5B | $2.8B | ||
| Q1 25 | $1.3B | $2.7B | ||
| Q4 24 | $1.2B | $2.7B | ||
| Q3 24 | $1.1B | $2.7B | ||
| Q2 24 | $998.4M | $2.6B |
| Q1 26 | — | $4.6B | ||
| Q4 25 | $3.2B | $4.4B | ||
| Q3 25 | $3.0B | $4.6B | ||
| Q2 25 | $3.5B | $4.7B | ||
| Q1 25 | $3.5B | $4.5B | ||
| Q4 24 | $3.1B | $4.5B | ||
| Q3 24 | $3.0B | $4.5B | ||
| Q2 24 | $2.9B | $4.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | 0.13× | ||
| Q3 25 | 0.68× | 0.12× | ||
| Q2 25 | 0.64× | 0.12× | ||
| Q1 25 | 1.21× | 0.13× | ||
| Q4 24 | 1.07× | 0.13× | ||
| Q3 24 | 1.21× | 0.12× | ||
| Q2 24 | 1.36× | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | — |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.3M | $399.8M | ||
| Q3 25 | $125.7M | $354.9M | ||
| Q2 25 | $196.5M | $-7.4M | ||
| Q1 25 | $63.8M | $-177.6M | ||
| Q4 24 | $147.7M | $378.9M | ||
| Q3 24 | $98.5M | $232.8M | ||
| Q2 24 | $96.5M | $57.7M |
| Q1 26 | — | — | ||
| Q4 25 | $48.2M | $388.5M | ||
| Q3 25 | $100.1M | $346.1M | ||
| Q2 25 | $177.9M | $-14.3M | ||
| Q1 25 | $51.5M | $-185.2M | ||
| Q4 24 | $94.1M | $370.9M | ||
| Q3 24 | $71.8M | $223.0M | ||
| Q2 24 | $74.0M | $51.3M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 24.6% | ||
| Q3 25 | 14.2% | 16.7% | ||
| Q2 25 | 27.4% | -0.7% | ||
| Q1 25 | 9.1% | -12.1% | ||
| Q4 24 | 15.7% | 21.1% | ||
| Q3 24 | 13.2% | 10.3% | ||
| Q2 24 | 15.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | 0.7% | ||
| Q3 25 | 3.6% | 0.4% | ||
| Q2 25 | 2.9% | 0.3% | ||
| Q1 25 | 2.2% | 0.5% | ||
| Q4 24 | 9.0% | 0.5% | ||
| Q3 24 | 4.9% | 0.5% | ||
| Q2 24 | 4.6% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | 5.57× | ||
| Q3 25 | 1.43× | 2.20× | ||
| Q2 25 | 8.73× | -0.04× | ||
| Q1 25 | 1.80× | -2.22× | ||
| Q4 24 | 1.47× | 3.91× | ||
| Q3 24 | 1.27× | 1.36× | ||
| Q2 24 | 0.51× | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
WSO
Segment breakdown not available.
